مصطلحات الفهرس: genetic counseling, adult, article, Australia, Australian, cardiomyopathy/si [Side Effect], clinical article, cohort analysis, compassionate use, creatinine blood level, death, drug efficacy, drug fatality/si [Side Effect], female, gastrointestinal hemorrhage/si [Side Effect], hemolytic uremic syndrome/dt [Drug Therapy], hemolytic uremic syndrome/su [Surgery], hemolytic uremic syndrome/th [Therapy], human, infant, iron deficiency anemia/si [Side Effect], kidney function, kidney graft rejection/co [Complication], kidney transplantation, lung embolism/si [Side Effect], male, neutropenia/si [Side Effect], posterior reversible encephalopathy syndrome/si [Side Effect], priority journal, recurrent disease, remission, renal replacement therapy, retrospective study, thrombotic thrombocytopenic purpura, treatment response, complement inhibitor/dt [Drug Therapy], creatinine/ec [Endogenous Compound], eculizumab/ae [Adverse Drug Reaction], eculizumab/do [Drug Dose], eculizumab/dt [Drug Therapy], eculizumab/iv [Intravenous Drug Administration], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40687Test
Internal Medicine Journal
Click here for full text options
LibKey Link

مصطلحات الفهرس: human, hypertension, hypokinesia, malaise, male, medical device, middle aged, muscle cramp, nausea and vomiting, noninvasive ventilation, spine surgery, takotsubo cardiomyopathy/co [Complication], takotsubo cardiomyopathy/di [Diagnosis], takotsubo cardiomyopathy/si [Side Effect], thorax radiography, transthoracic echocardiography, withdrawal syndrome/co [Complication], withdrawal syndrome/di [Diagnosis], withdrawal syndrome/si [Side Effect], acetylsalicylic acid, clonidine/ae [Adverse Drug Reaction], clonidine/dt [Drug Therapy], clonidine/tl [Intrathecal Drug Administration], clonidine/iv [Intravenous Drug Administration], clonidine/po [Oral Drug Administration], clopidogrel/po [Oral Drug Administration], diazepam/dt [Drug Therapy], diazepam/iv [Intravenous Drug Administration], glyceryl trinitrate/dt [Drug Therapy], glyceryl trinitrate/iv [Intravenous Drug Administration], glyceryl trinitrate/li [Sublingual Drug Administration], metoprolol/po [Oral Drug Administration], opiate/dt [Drug Therapy], opiate/po [Oral Drug Administration], ramipril/po [Oral Drug Administration], troponin I/ec [Endogenous Compound], clonidine intrathecal pump, thorax pain, adult, angiography, anxiety disorder/dt [Drug Therapy], article, backache/dt [Drug Therapy], backache/rh [Rehabilitation], case report, collapse, coronary artery obstruction, diaphoresis, drug dose titration, dyspnea, electrocardiography, headache, hemodynamics, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40046Test
Journal of Medical Toxicology
Click here for full text options
LibKey Link

مصطلحات الفهرس: genetic counseling, adult, article, Australia, Australian, cardiomyopathy/si [Side Effect], clinical article, cohort analysis, compassionate use, creatinine blood level, death, drug efficacy, drug fatality/si [Side Effect], female, gastrointestinal hemorrhage/si [Side Effect], hemolytic uremic syndrome/dt [Drug Therapy], hemolytic uremic syndrome/su [Surgery], hemolytic uremic syndrome/th [Therapy], human, infant, iron deficiency anemia/si [Side Effect], kidney function, kidney graft rejection/co [Complication], kidney transplantation, lung embolism/si [Side Effect], male, neutropenia/si [Side Effect], posterior reversible encephalopathy syndrome/si [Side Effect], priority journal, recurrent disease, remission, renal replacement therapy, retrospective study, thrombotic thrombocytopenic purpura, treatment response, complement inhibitor/dt [Drug Therapy], creatinine/ec [Endogenous Compound], eculizumab/ae [Adverse Drug Reaction], eculizumab/do [Drug Dose], eculizumab/dt [Drug Therapy], eculizumab/iv [Intravenous Drug Administration], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40687Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: human, hypertension, hypokinesia, malaise, male, medical device, middle aged, muscle cramp, nausea and vomiting, noninvasive ventilation, spine surgery, takotsubo cardiomyopathy/co [Complication], takotsubo cardiomyopathy/di [Diagnosis], takotsubo cardiomyopathy/si [Side Effect], thorax radiography, transthoracic echocardiography, withdrawal syndrome/co [Complication], withdrawal syndrome/di [Diagnosis], withdrawal syndrome/si [Side Effect], acetylsalicylic acid, clonidine/ae [Adverse Drug Reaction], clonidine/dt [Drug Therapy], clonidine/tl [Intrathecal Drug Administration], clonidine/iv [Intravenous Drug Administration], clonidine/po [Oral Drug Administration], clopidogrel/po [Oral Drug Administration], diazepam/dt [Drug Therapy], diazepam/iv [Intravenous Drug Administration], glyceryl trinitrate/dt [Drug Therapy], glyceryl trinitrate/iv [Intravenous Drug Administration], glyceryl trinitrate/li [Sublingual Drug Administration], metoprolol/po [Oral Drug Administration], opiate/dt [Drug Therapy], opiate/po [Oral Drug Administration], ramipril/po [Oral Drug Administration], troponin I/ec [Endogenous Compound], clonidine intrathecal pump, thorax pain, adult, angiography, anxiety disorder/dt [Drug Therapy], article, backache/dt [Drug Therapy], backache/rh [Rehabilitation], case report, collapse, coronary artery obstruction, diaphoresis, drug dose titration, dyspnea, electrocardiography, headache, hemodynamics, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40046Test
Journal of Medical Toxicology
LibKey Link

مصطلحات الفهرس: endometrium cancer/dt [Drug Therapy], enzyme inhibition, estrogen receptor positive breast cancer/dt [Drug Therapy], fatigue/si [Side Effect], gastrointestinal symptom/si [Side Effect], gene mutation, genetic transcription, human, hyperglycemia/si [Side Effect], hyperlipidemia/si [Side Effect], hypertension/si [Side Effect], hypoglycemia/si [Side Effect], hypophosphatemia/si [Side Effect], interstitial pneumonia/si [Side Effect], ischemic cardiomyopathy/si [Side Effect], kidney carcinoma/dt [Drug Therapy], lactic acidosis/si [Side Effect], lung non small cell cancer/dt [Drug Therapy], mantle cell lymphoma/dt [Drug Therapy], maximum tolerated dose, molecular interaction, mood disorder/si [Side Effect], mucosa inflammation/si [Side Effect], myeloma/dt [Drug Therapy], nausea/si [Side Effect], neoplasm, nonhuman, pancreas cancer/dt [Drug Therapy], pancreatic neuroendocrine tumor/dt [Drug Therapy], pharmacodynamics, phase 1 clinical trial (topic), priority journal, review, side effect/si [Side Effect], signal transduction, skin toxicity/si [Side Effect], solid tumor/dt [Drug Therapy], Streptomyces hygroscopicus, thrombocyte rich plasma, thrombocytopenia/si [Side Effect], treatment response, urogenital tract cancer/dt [Drug Therapy], uterine cervix cancer/dt [Drug Therapy], vomiting/si [Side Effect], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/ct [Clinical Trial], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/dt [Drug Therapy], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/pd [Pharmacology], 2 (2 difluoromethylbenzimidazol 1 yl) 4,6 dimorpholino 1,3,5 triazine/ct [Clinical Trial], 2 (2 difluoromethylbenzimidazol 1 yl) 4,6 dimorpholino 1,3,5 triazine/pd [Pharmacology], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/ae [Adverse Drug Reaction], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/ct [Clinical Trial], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/pd [Pharmacology], 4 [2 (4 amino 1,2,5 oxadiazol 3 yl) 1 ethyl 7 (3 piperidinylmethoxy) 1h imidazo[4,5 c]pyridin 4 yl] 2 methyl 3 butyn 2 ol/ct [Clinical Trial], 4 [2 (4 amino 1,2,5 oxadiazol 3 yl) 1 ethyl 7 (3 piperidinylmethoxy) 1h imidazo[4,5 c]pyridin 4 yl] 2 methyl 3 butyn 2 ol/pd [Pharmacology], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/ae [Adverse Drug Reaction], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/ct [Clinical Trial], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/pd [Pharmacology], 1 (4 oxo 8 phenyl 4h 1 benzopyran 2 yl)morpholinio, azd 2014/ae [Adverse Drug Reaction], azd 2014/ct [Clinical Trial], azd 2014/dt [Drug Therapy], azd 2014/pk [Pharmacokinetics], azd 2014/pd [Pharmacology], azd 8055/ae [Adverse Drug Reaction], azd 8055/ct [Clinical Trial], azd 8055/dt [Drug Therapy], azd 8055/pd [Pharmacology], buparlisib/ae [Adverse Drug Reaction], buparlisib/ct [Clinical Trial], buparlisib/pd [Pharmacology], everolimus/ct [Clinical Trial], everolimus/dt [Drug Therapy], everolimus/pd [Pharmacology], interferon/cb [Drug Combination], interferon/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/ct [Clinical Trial], phosphatidylinositol 3 kinase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/iv [Intravenous Drug Administration], phosphatidylinositol 3 kinase inhibitor/po [Oral Drug Administration], phosphatidylinositol 3 kinase inhibitor/pk [Pharmacokinetics], phosphatidylinositol 3 kinase inhibitor/pd [Pharmacology], pictilisib/ae [Adverse Drug Reaction], pictilisib/ct [Clinical Trial], pictilisib/dt [Drug Therapy], pictilisib/pd [Pharmacology], ridaforolimus/ae [Adverse Drug Reaction], ridaforolimus/ct [Clinical Trial], ridaforolimus/pd [Pharmacology], temsirolimus/ct [Clinical Trial], temsirolimus/cb [Drug Combination], temsirolimus/dt [Drug Therapy], temsirolimus/pd [Pharmacology], unclassified drug, unindexed drug, xl 147/ae [Adverse Drug Reaction], xl 147/ct [Clinical Trial], xl 147/dt [Drug Therapy], xl 147/pd [Pharmacology], xl 765/ae [Adverse Drug Reaction], xl 765/ct [Clinical Trial], xl 765/pd [Pharmacology], azd 5363/ct [Clinical Trial], azd 5363/po [Oral Drug Administration], azd 5363/pd [Pharmacology], bay 80 6946/ae [Adverse Drug Reaction], bay 80 6946/ct [Clinical Trial], bay 80 6946/dt [Drug Therapy], bay 80 6946/iv [Intravenous Drug Administration], bay 80 6946/pd [Pharmacology], ds 7423/ct [Clinical Trial], gdc 0980/ae [Adverse Drug Reaction], gdc 0980/ct [Clinical Trial], gdc 0980/dt [Drug Therapy], gdc 0980/pd [Pharmacology], gsk 141795/ae [Adverse Drug Reaction], gsk 141795/ct [Clinical Trial], gsk 141795/pd [Pharmacology], gsk 2126458/ae [Adverse Drug Reaction], gsk 2126458/ct [Clinical Trial], gsk 2126458/dt [Drug Therapy], gsk 2126458/pd [Pharmacology], ink 128/ct [Clinical Trial], ink 128/dt [Drug Therapy], ink 128/pd [Pharmacology], ly 2780301/ct [Clinical Trial], ly 2780301/pk [Pharmacokinetics], ly 2780301/pd [Pharmacology], pf 04691502/ae [Adverse Drug Reaction], pf 04691502/ct [Clinical Trial], pf 04691502/dt [Drug Therapy], pf 04691502/po [Oral Drug Administration], pf 04691502/pd [Pharmacology], pki 587/ae [Adverse Drug Reaction], pki 587/ct [Clinical Trial], pki 587/dt [Drug Therapy], pki 587/iv [Intravenous Drug Administration], pki 587/pd [Pharmacology], pwt 33597/ct [Clinical Trial], pwt 33597/dt [Drug Therapy], pwt 33597/pd [Pharmacology], sar 254409/ae [Adverse Drug Reaction], sar 254409/ct [Clinical Trial], sar 254409/pd [Pharmacology], phase 3 clinical trial (topic), adrenal cortex carcinoma/dt [Drug Therapy], aminotransferase blood level, anorexia/si [Side Effect], bladder cancer/dt [Drug Therapy], breast cancer/dt [Drug Therapy], cancer chemotherapy, cancer survival, clinical trial (topic), diarrhea/si [Side Effect], drug dose escalation, drug dose increase, drug efficacy, drug eruption/si [Side Effect], drug intermittent therapy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27530Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: endometrium cancer/dt [Drug Therapy], enzyme inhibition, estrogen receptor positive breast cancer/dt [Drug Therapy], fatigue/si [Side Effect], gastrointestinal symptom/si [Side Effect], gene mutation, genetic transcription, human, hyperglycemia/si [Side Effect], hyperlipidemia/si [Side Effect], hypertension/si [Side Effect], hypoglycemia/si [Side Effect], hypophosphatemia/si [Side Effect], interstitial pneumonia/si [Side Effect], ischemic cardiomyopathy/si [Side Effect], kidney carcinoma/dt [Drug Therapy], lactic acidosis/si [Side Effect], lung non small cell cancer/dt [Drug Therapy], mantle cell lymphoma/dt [Drug Therapy], maximum tolerated dose, molecular interaction, mood disorder/si [Side Effect], mucosa inflammation/si [Side Effect], myeloma/dt [Drug Therapy], nausea/si [Side Effect], neoplasm, nonhuman, pancreas cancer/dt [Drug Therapy], pancreatic neuroendocrine tumor/dt [Drug Therapy], pharmacodynamics, phase 1 clinical trial (topic), priority journal, review, side effect/si [Side Effect], signal transduction, skin toxicity/si [Side Effect], solid tumor/dt [Drug Therapy], Streptomyces hygroscopicus, thrombocyte rich plasma, thrombocytopenia/si [Side Effect], treatment response, urogenital tract cancer/dt [Drug Therapy], uterine cervix cancer/dt [Drug Therapy], vomiting/si [Side Effect], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/ct [Clinical Trial], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/dt [Drug Therapy], 1 (1 cyano 1 methylethyl) 3 methyl 8 (3 quinolinyl)imidazo[4,5 c]quinolin 2(1h,3h) one/pd [Pharmacology], 2 (2 difluoromethylbenzimidazol 1 yl) 4,6 dimorpholino 1,3,5 triazine/ct [Clinical Trial], 2 (2 difluoromethylbenzimidazol 1 yl) 4,6 dimorpholino 1,3,5 triazine/pd [Pharmacology], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/ae [Adverse Drug Reaction], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/ct [Clinical Trial], 4 (4 amino 5 (7 methoxy 1h indol 2 yl)imidazo[5,1 f][1,2,4]triazin 7 yl)cyclohexanecarboxylic acid/pd [Pharmacology], 4 [2 (4 amino 1,2,5 oxadiazol 3 yl) 1 ethyl 7 (3 piperidinylmethoxy) 1h imidazo[4,5 c]pyridin 4 yl] 2 methyl 3 butyn 2 ol/ct [Clinical Trial], 4 [2 (4 amino 1,2,5 oxadiazol 3 yl) 1 ethyl 7 (3 piperidinylmethoxy) 1h imidazo[4,5 c]pyridin 4 yl] 2 methyl 3 butyn 2 ol/pd [Pharmacology], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/ae [Adverse Drug Reaction], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/ct [Clinical Trial], 4 diallylaminomethylene 1,3,4,7,10,11,12,13,14,15,16,17 dodecahydro 6 hydroxy 1 methoxymethyl 10,13 dimethyl 3,7,17 trioxo 2 oxacyclopenta[a]phenanthren 11 yl acetate/pd [Pharmacology], 1 (4 oxo 8 phenyl 4h 1 benzopyran 2 yl)morpholinio, azd 2014/ae [Adverse Drug Reaction], azd 2014/ct [Clinical Trial], azd 2014/dt [Drug Therapy], azd 2014/pk [Pharmacokinetics], azd 2014/pd [Pharmacology], azd 8055/ae [Adverse Drug Reaction], azd 8055/ct [Clinical Trial], azd 8055/dt [Drug Therapy], azd 8055/pd [Pharmacology], buparlisib/ae [Adverse Drug Reaction], buparlisib/ct [Clinical Trial], buparlisib/pd [Pharmacology], everolimus/ct [Clinical Trial], everolimus/dt [Drug Therapy], everolimus/pd [Pharmacology], interferon/cb [Drug Combination], interferon/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/ct [Clinical Trial], phosphatidylinositol 3 kinase inhibitor/dt [Drug Therapy], phosphatidylinositol 3 kinase inhibitor/iv [Intravenous Drug Administration], phosphatidylinositol 3 kinase inhibitor/po [Oral Drug Administration], phosphatidylinositol 3 kinase inhibitor/pk [Pharmacokinetics], phosphatidylinositol 3 kinase inhibitor/pd [Pharmacology], pictilisib/ae [Adverse Drug Reaction], pictilisib/ct [Clinical Trial], pictilisib/dt [Drug Therapy], pictilisib/pd [Pharmacology], ridaforolimus/ae [Adverse Drug Reaction], ridaforolimus/ct [Clinical Trial], ridaforolimus/pd [Pharmacology], temsirolimus/ct [Clinical Trial], temsirolimus/cb [Drug Combination], temsirolimus/dt [Drug Therapy], temsirolimus/pd [Pharmacology], unclassified drug, unindexed drug, xl 147/ae [Adverse Drug Reaction], xl 147/ct [Clinical Trial], xl 147/dt [Drug Therapy], xl 147/pd [Pharmacology], xl 765/ae [Adverse Drug Reaction], xl 765/ct [Clinical Trial], xl 765/pd [Pharmacology], azd 5363/ct [Clinical Trial], azd 5363/po [Oral Drug Administration], azd 5363/pd [Pharmacology], bay 80 6946/ae [Adverse Drug Reaction], bay 80 6946/ct [Clinical Trial], bay 80 6946/dt [Drug Therapy], bay 80 6946/iv [Intravenous Drug Administration], bay 80 6946/pd [Pharmacology], ds 7423/ct [Clinical Trial], gdc 0980/ae [Adverse Drug Reaction], gdc 0980/ct [Clinical Trial], gdc 0980/dt [Drug Therapy], gdc 0980/pd [Pharmacology], gsk 141795/ae [Adverse Drug Reaction], gsk 141795/ct [Clinical Trial], gsk 141795/pd [Pharmacology], gsk 2126458/ae [Adverse Drug Reaction], gsk 2126458/ct [Clinical Trial], gsk 2126458/dt [Drug Therapy], gsk 2126458/pd [Pharmacology], ink 128/ct [Clinical Trial], ink 128/dt [Drug Therapy], ink 128/pd [Pharmacology], ly 2780301/ct [Clinical Trial], ly 2780301/pk [Pharmacokinetics], ly 2780301/pd [Pharmacology], pf 04691502/ae [Adverse Drug Reaction], pf 04691502/ct [Clinical Trial], pf 04691502/dt [Drug Therapy], pf 04691502/po [Oral Drug Administration], pf 04691502/pd [Pharmacology], pki 587/ae [Adverse Drug Reaction], pki 587/ct [Clinical Trial], pki 587/dt [Drug Therapy], pki 587/iv [Intravenous Drug Administration], pki 587/pd [Pharmacology], pwt 33597/ct [Clinical Trial], pwt 33597/dt [Drug Therapy], pwt 33597/pd [Pharmacology], sar 254409/ae [Adverse Drug Reaction], sar 254409/ct [Clinical Trial], sar 254409/pd [Pharmacology], phase 3 clinical trial (topic), adrenal cortex carcinoma/dt [Drug Therapy], aminotransferase blood level, anorexia/si [Side Effect], bladder cancer/dt [Drug Therapy], breast cancer/dt [Drug Therapy], cancer chemotherapy, cancer survival, clinical trial (topic), diarrhea/si [Side Effect], drug dose escalation, drug dose increase, drug efficacy, drug eruption/si [Side Effect], drug intermittent therapy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27530Test
LibKey Link

مصطلحات الفهرس: fever/si [Side Effect], tachycardia/si [Side Effect], clozapine/ae [Adverse Drug Reaction], clozapine/dt [Drug Therapy], aged, ataxia/si [Side Effect], bipolar disorder/dt [Drug Therapy], cardiomyopathy/si [Side Effect], cerebrovascular disease, chronic obstructive lung disease, comorbidity, diabetes mellitus, drug safety, drug tolerability, drug withdrawal, dyslipidemia, dysphagia/si [Side Effect], electrocardiogram, female, gastroesophageal reflux, heart atrium fibrillation, heart infarction/si [Side Effect], heart muscle ischemia, human, hypertension, leukopenia, major clinical study, male, myocarditis/si [Side Effect], orthostatic hypotension/si [Side Effect], Parkinson disease/dt [Drug Therapy], parkinsonism/si [Side Effect], psychopharmacology, review, schizoaffective psychosis/dt [Drug Therapy], schizophrenia/dt [Drug Therapy], sedation, senescence, side effect/si [Side Effect], stroke, Review

URL: Click here for full text options
LibKey Link

مصطلحات الفهرس: chronic lung disease/pc [Prevention], chronic lung disease/th [Therapy], clinical trial, Cochrane Library, diet supplementation, disease association, diuresis, drug dose reduction, drug potentiation, duodenum perforation/si [Side Effect], echocardiography, electrolyte disturbance/si [Side Effect], evidence based medicine, family history, fiberoptic bronchoscopy, gastroduodenal ulcer/si [Side Effect], gastrointestinal symptom/dt [Drug Therapy], gastrointestinal symptom/pc [Prevention], genetic polymorphism, genetic predisposition, glucose intolerance/si [Side Effect], human, hypercalciuria/si [Side Effect], hypertension/si [Side Effect], hypertrophic obstructive cardiomyopathy/si [Side Effect], incidence, interstitial pneumonia, intrauterine infection, kidney calcification/si [Side Effect], leukomalacia/si [Side Effect], lipid diet, long term care, magnesium deficiency, meta analysis, monotherapy, nebulization, nephrolithiasis/si [Side Effect], newborn intensive care, oxygen therapy, oxygen toxicity/co [Complication], patent ductus arteriosus, pathogenesis, pertussis/dt [Drug Therapy], pertussis/pc [Prevention], positive end expiratory pressure, prematurity/dt [Drug Therapy], prematurity/pc [Prevention], prognosis, protein degradation, pulmonary hypertension/co [Complication], pulmonary hypertension/di [Diagnosis], pulmonary hypertension/dt [Drug Therapy], pulmonary hypertension/pc [Prevention], respiratory tract infection, retinol deficiency/dt [Drug Therapy], retinol deficiency/pc [Prevention], risk benefit analysis, secondary hyperparathyroidism/si [Side Effect], selenium deficiency, sepsis/si [Side Effect], side effect/si [Side Effect], systematic review, therapy delay, tidal volume, urea nitrogen blood level, virus infection/dt [Drug Therapy], beclometasone dipropionate/dt [Drug Therapy], bronchodilating agent/dt [Drug Therapy], chlorothiazide/cb [Drug Combination], chlorothiazide/dt [Drug Therapy], chlorothiazide/po [Oral Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/do [Drug Dose], dexamethasone/dt [Drug Therapy], dexamethasone/pd [Pharmacology], diuretic agent/cb [Drug Combination], diuretic agent/it [Drug Interaction], diuretic agent/dt [Drug Therapy], furosemide/ae [Adverse Drug Reaction], furosemide/cb [Drug Combination], furosemide/dt [Drug Therapy], furosemide/iv [Intravenous Drug Administration], furosemide/po [Oral Drug Administration], helium/dt [Drug Therapy], hydrochlorothiazide/cb [Drug Combination], hydrochlorothiazide/dt [Drug Therapy], hydrochlorothiazide/po [Oral Drug Administration], indometacin/ct [Clinical Trial], indometacin/dt [Drug Therapy], ipratropium bromide/dt [Drug Therapy], isoetarine/dt [Drug Therapy], isoprenaline/dt [Drug Therapy], nifedipine/dt [Drug Therapy], nifedipine/po [Oral Drug Administration], nitric oxide/dt [Drug Therapy], nitric oxide/ih [Inhalational Drug Administration], orciprenaline/dt [Drug Therapy], oxygen, pertussis vaccine/dt [Drug Therapy], protirelin/cb [Drug Combination], protirelin/dt [Drug Therapy], ranitidine/dt [Drug Therapy], ranitidine/iv [Intravenous Drug Administration], recombinant erythropoietin/dt [Drug Therapy], retinol/dt [Drug Therapy], ribavirin/dt [Drug Therapy], salbutamol/ae [Adverse Drug Reaction], salbutamol/ad [Drug Administration], salbutamol/dt [Drug Therapy], salbutamol/iv [Intravenous Drug Administration], salbutamol/po [Oral Drug Administration], sildenafil/dt [Drug Therapy], spironolactone/cb [Drug Combination], spironolactone/dt [Drug Therapy], spironolactone/po [Oral Drug Administration], steroid/ct [Clinical Trial], steroid/dt [Drug Therapy], steroid/ih [Inhalational Drug Administration], steroid/pd [Pharmacology], theophylline/cb [Drug Combination], theophylline/it [Drug Interaction], theophylline/dt [Drug Therapy], unindexed drug, uterus spasmolytic agent/dt [Drug Therapy], lung compliance, amino acid blood level, antioxidant activity, article, artificial ventilation, balloon dilatation, body weight disorder/si [Side Effect], bronchospasm, cardiovascular disease/si [Side Effect], cholelithiasis/si [Side Effect], chorioamnionitis, chronic lung disease/cn [Congenital Disorder], chronic lung disease/di [Diagnosis], chronic lung disease/dt [Drug Therapy], chronic lung disease/et [Etiology], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31781Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: schizophrenia/dt [Drug Therapy], selenium deficiency/si [Side Effect], trace metal blood level, clozapine/ae [Adverse Drug Reaction], clozapine/do [Drug Dose], clozapine/dt [Drug Therapy], clozapine/pd [Pharmacology], selenium/cr [Drug Concentration], myocarditis/si [Side Effect], adult, agranulocytosis/si [Side Effect], article, blood sampling, cardiomyopathy/si [Side Effect], catecholamine metabolism, dietary intake, female, human, major clinical study, male, oxidative stress, priority journal, risk benefit analysis, schizophrenia/di [Diagnosis], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: fever/si [Side Effect], tachycardia/si [Side Effect], clozapine/ae [Adverse Drug Reaction], clozapine/dt [Drug Therapy], aged, ataxia/si [Side Effect], bipolar disorder/dt [Drug Therapy], cardiomyopathy/si [Side Effect], cerebrovascular disease, chronic obstructive lung disease, comorbidity, diabetes mellitus, drug safety, drug tolerability, drug withdrawal, dyslipidemia, dysphagia/si [Side Effect], electrocardiogram, female, gastroesophageal reflux, heart atrium fibrillation, heart infarction/si [Side Effect], heart muscle ischemia, human, hypertension, leukopenia, major clinical study, male, myocarditis/si [Side Effect], orthostatic hypotension/si [Side Effect], Parkinson disease/dt [Drug Therapy], parkinsonism/si [Side Effect], psychopharmacology, review, schizoaffective psychosis/dt [Drug Therapy], schizophrenia/dt [Drug Therapy], sedation, senescence, side effect/si [Side Effect], stroke, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/30951Test
LibKey Link